Intelligent Bio Solutions vs Neuraxis
Intelligent Bio Solutions reported revenue of $4 million in fiscal 2026, 1.2 times Neuraxis' $4 million in fiscal 2025. Intelligent Bio Solutions' revenue grew 38.1% in its latest year, and Neuraxis' grew 32.9%. Intelligent Bio Solutions had an operating margin of -299.1%, against -219.4% at Neuraxis. Free cash flow was −$12 million at Intelligent Bio Solutions and −$6 million at Neuraxis. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Intelligent Bio Solutions | Neuraxis | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $4M |
| Revenue growth | 38.1% | 32.9% |
| Revenue growth a year, last 5 years | 16.0% | — |
| Gross margin | 48.6% | 84.2% |
| Operating margin | −299.1% | −219.4% |
| Net margin | −294.9% | −218.6% |
| Free cash flow | −$12M | −$6M |
| Free cash flow margin | −285.9% | −181.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 179.3% | 31.3% |
| Last close | $1.51 | $4.50 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $1.4 million, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Intelligent Bio SolutionsNeuraxis
Operating margin
Percent of revenue
Intelligent Bio SolutionsNeuraxis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Intelligent Bio SolutionsNeuraxis
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Intelligent Bio Solutions and Neuraxis pages.